Assignee
DIZAL JIANGSU PHARMACEUTICAL CO LTD
CN·18 granted patents·10 pending applications·22 citations·filing 2017–2023
Top patents by PatentIndex Score
28 records- 0193US10822334B2ErbB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Nov 3, 2020·4 cites·6 claims
- 0287US11007198B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted May 18, 2021·2 cites·5 claims
- 0386US11247983B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 15, 2022·2 cites·19 claims
- 0486US10167276B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2017·Granted Jan 1, 2019·5 cites·5 claims
- 0584US11274091B2Cyclopentane compoundsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Mar 15, 2022·2 cites·9 claims
- 0684US10654835B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2018·Granted May 19, 2020·3 cites·22 claims
- 0783US11084827B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Aug 10, 2021·1 cites·18 claims
- 0883US10898481B2Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Jan 26, 2021·1 cites·6 claims
- 0982US11504375B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 22, 2022·1 cites·23 claims
- 1082US10858365B2Triazolo-pyrimidine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Dec 8, 2020·1 cites·9 claims
- 1179US12503473B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Granted Dec 23, 2025·0 cites·6 claims
- 1275US12319670B2Compounds and methods for inhibiting JAKDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Jun 3, 2025·0 cites·24 claims
- 1375US11896597B2ErbB/BTK inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Granted Feb 13, 2024·0 cites·20 claims
- 1473US2023135068A1Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1573US2025057850A1Erbb/btk inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1670US11851432B2Triazolopyrimidine compounds and their use in treating cancerDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Dec 26, 2023·0 cites·20 claims
- 1766US11571420B2Pyrazine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Feb 7, 2023·0 cites·22 claims
- 1861US11629147B2Triazolo-pyrimidine compounds and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Apr 18, 2023·0 cites·24 claims
- 1961US11447492B2ERBB receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Granted Sep 20, 2022·0 cites·15 claims
- 2061US2022411422A1Erbb receptor inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2161US2025346616A1Rock inhibitors and uses thereofDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 2259US12378218B2Cyclopentane compoundsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2021·Granted Aug 5, 2025·0 cites·15 claims
- 2355US2025197377A1Novel pharmaceutical salts and polymorphic forms of an erbb and btk inhibitorDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 2452US2023055566A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2552US2023052256A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2652US2023052680A1Novel anti-fgfr2b antibodiesDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2750US2022242884A1Dna-dependent protein kinase inhibitorDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
- 2849US2023122807A1Btk inhibitorsDIZAL JIANGSU PHARMACEUTICAL CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when DIZAL JIANGSU PHARMACEUTICAL CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →